Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors
Ontology highlight
ABSTRACT: This is a Phase 1b/2 study to determine the recommended phase 2 dose (RP2D), safety and tolerability, pharmacokinetics (PK) and clinical activity of the glutaminase inhibitor CB-839 with the poly adenosine diphosphate ribose polymerase (PARP) inhibitor talazoparib in participants with advanced/metastatic solid tumors.
DISEASE(S): Tnbc - Triple-negative Breast Cancer,Rcc,Solid Tumor,Crc,Triple Negative Breast Neoplasms,Clear Cell Renal Cell Carcinoma,Colorectal Cancer,Carcinoma, Renal Cell,Ccrcc
PROVIDER: 2299826 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA